Predicting the Rate of Cognitive Decline in Alzheimer Disease: Data From the ICTUS Study
Por:
Canevelli, M, Kelaiditi, E, del Campo, N, Bruno, G, Vellas, B, Cesari, M, Salvà A., Coley, Nicola
Publicada:
1 jul 2016
Resumen:
Background:Different rates of cognitive progression have been observed among Alzheimer disease (AD) patients. The present study aimed at evaluating whether the rate of cognitive worsening in AD may be predicted by widely available and easy-to-assess factors.Methods:Mild to moderate AD patients were recruited in the ICTUS study. Multinomial logistic regression analysis was performed to measure the association between several sociodemographic and clinical variables and 3 different rates of cognitive decline defined by modifications (after 1 year of follow-up) of the Mini Mental State Examination (MMSE) score: (1) slow progression, as indicated by a decrease in the MMSE score 1 point; (2) intermediate progression, decrease in the MMSE score between 2 and 5 points; and (3) rapid progression, decrease in the MMSE score 6 points.Results:A total of 1005 patients were considered for the present analyses. Overall, most of the study participants (52%) exhibited a slow cognitive course. Higher ADAS-Cog scores at baseline were significantly associated with both intermediate and rapid decline. Conversely, increasing age was negatively associated with rapid cognitive worsening.Conclusions:A slow progression of cognitive decline is common among AD patients. The influence of age and baseline cognitive impairment should always be carefully considered when designing AD trials and defining study populations.
Filiaciones:
Canevelli, M:
Univ Roma La Sapienza, Dept Neurol & Psychiat, Memory Clin, Viale Univ 30, I-00185 Rome, Italy
Toulouse Univ Hosp, Gerontopole, Toulouse, France
Kelaiditi, E:
Toulouse Univ Hosp, Gerontopole, Toulouse, France
del Campo, N:
Toulouse Univ Hosp, Gerontopole, Toulouse, France
Bruno, G:
Univ Roma La Sapienza, Dept Neurol & Psychiat, Memory Clin, Viale Univ 30, I-00185 Rome, Italy
Vellas, B:
Toulouse Univ Hosp, Gerontopole, Toulouse, France
Inserm UMR1027, Toulouse, France
Univ Toulouse 3, Inst Aging, Toulouse, France
Cesari, M:
Toulouse Univ Hosp, Gerontopole, Toulouse, France
Inserm UMR1027, Toulouse, France
Univ Toulouse 3, Inst Aging, Toulouse, France
Salvà A.:
Institut dInvestigació Biomèdica Sant Pau (IIB Sant Pau), Barceona, Spain
Coley, Nicola :
CHU de Toulouse, Toulouse, France
Green Accepted
|